Cardiovascular Diseases Research (93.837)
Cardiovascular Diseases Research (Assistance Listing 93.837) is run by the National Institutes of Health, part of the Department of Health and Human Services. It awarded $15 billion in 11,797 grants from fiscal 2021 to 2025, about $1.2 million per award on average. 82 funding opportunities are open or forecast now.
The typical award was $783,601. Half of the 11,796 awards fell between $321,849 and $1.9 million, and they ranged from $0 to $39.1 million.
- Awarded, FY 2021 to 2025$15 billion
- Grant awards11,797
- Typical award$783,601
- Awarded in FY 2025$3.0 billion
- Size rank39 of 1824
- Type of assistanceProject grants
Key findings
- Annual funding rose from $2.8 billion in fiscal 2021 to $3.0 billion in fiscal 2025.
- It is the 39th largest of 1,824 federal grant programs by five-year awards.
- The 20 largest recipients received 39% of the money.
- Awards went to recipients in 51 states and territories.
What the program funds
The National Heart, Lung, and Blood Institute (NHLBI) provides global leadership for a research, training, and education program to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives. To foster heart and vascular research in the basic, translational, clinical and population sciences, and to foster training to build talented young investigators in these areas, funded through competitive research training grants. Small Business Innovation Research (SBIR) program: To stimulate technological innovation; use small business to meet Federal research and development needs; foster and encourage participation in innovation and entrepreneurship by socially and economically disadvantaged persons; and increase private-sector commercialization of innovations derived from Federal research and development funding. Small Business Technology Transfer (STTR) program: To stimulate technological innovation; foster technology transfer through cooperative R&D between small businesses and research institutions, and increase private sector commercialization of innovations derived from federal R&D.
Open opportunities
- Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)
- Emerging Global Leader Award (K43 Independent Clinical Trial Required)
- NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed)
- Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)
- Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)
- NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
- NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
- Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed)
- NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
- NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
- Short Courses on Innovative Methodologies and Approaches in the Behavioral and Social Sciences (R25 Clinical Trials Not Allowed)
- NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)
- NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional)
- Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed)
- Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Required)
- Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed)
- Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required)
- Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed)
- NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)
- NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)
- Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required)
- Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Not Allowed)
- Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required)
- Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required)
Rules from the program listing
Who can apply
Local (includes State-designated Indian Tribes; excludes institutions of higher education and hospitals), Public nonprofit institution/organization (includes institutions of higher education and hospitals), Individual/Family, Small business (less than 500 employees), Private nonprofit institution/organization (includes institutions of higher education and hospitals) . Any nonprofit organization engaged in biomedical research and institutions or companies organized for profit may apply for almost any kind of grant. Only domestic, non-profit, private or public institutions may apply for NRSA Institutional Research Training Grants. An individual may apply for an NRSA or, in some cases, for a research grant if adequate facilities to perform the research are available. SBIR grants can be awarded only to United States small business concerns (entities that are independently owned and operated for profit or owned by another small business that itself is independently owned and operated for profit, or owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these and have no more than 500 employees including affiliates). Primary employment (more than one-half time) of the principal investigator must be with the small business at the time of award and during the conduct of the proposed project. In both Phase I and Phase II, the research must be performed in the U.S.
What the money can and cannot pay for
Grants may support stipends, research expenses, supplies, travel, childcare costs, and research training tuition as required to perform the research effort. Restrictions or limitations are imposed against the use of funds for entertainment, foreign travel, general-purpose equipment, alterations and renovations, and other items not regularly required for the performance of research. Individual predoctoral and postdoctoral national research service awards (NRSAs) are made directly to individuals through their universities for research training in heart and vascular diseases. NRSA awards may be made to eligible institutions to enable them to appoint individuals selected by the institution for research training. Certain service and payback provisions may apply to postdoctoral individuals upon termination of the award or termination of the appointment. SBIR Phase I awards (of approximately 6 to 24 months in duration) are to establish the scientific and technical merit of the proposed research effort, and feasibility of ideas that appear to have commercial potential. Direct to Phase II SBIR awards are for projects that have been developed beyond the feasibility phase using resources other than NIH Phase I awards that meet program needs and exhibit potential for commercial application. SBIR Phase IIB awards are for promising projects that require additional time and funding to advance to commercialization as well as ultimate approval or clearance by a Federal regulatory agency.
Matching requirements
This program has no statutory formula. Matching requirements are not applicable to this assistance listing. MOE requirements are not applicable to this assistance listing.
Deadlines
Contact the headquarters or regional location, as appropriate for application deadlines
Award range and average, in the agency's words
Grants: $1 to $30,000,000; $582,909. SBIR Phase I - $332,305; Phase II - up to $822,021; STTR Phase I - $247,844; Phase II - $268,497.
Funding history and past recipients
From fiscal 2021 to 2025, Cardiovascular Diseases Research (93.837) awarded$15 billion across 11,797 grant awards, an average of $1.2 million per award.
Who usually wins
Colleges and universities received 70% of the money, nonprofits 23% and small businesses 4.1%.
| Recipient type | Awards | Amount | Share |
|---|---|---|---|
| Colleges and universities | 8,294 | $10 billion | 70% |
| Nonprofits | 2,363 | $3.3 billion | 23% |
| Small businesses | 637 | $602 million | 4.1% |
| Other | 486 | $515 million | 3.5% |
| Businesses | 8 | $26.7 million | 0.2% |
| State and local governments | 8 | $10.7 million | less than 0.1% |
| Tribal governments and organizations | 1 | $1.9 million | less than 0.1% |
By state
50 states have a page for this program: those that received at least $1 million or 10 awards.
| State | Awards | Amount |
|---|---|---|
| California | 1,464 | $1.8 billion |
| Massachusetts | 1,118 | $1.5 billion |
| New York | 895 | $1.4 billion |
| Pennsylvania | 943 | $1.1 billion |
| Ohio | 581 | $752 million |
| Illinois | 484 | $677 million |
| Texas | 546 | $635 million |
| North Carolina | 487 | $628 million |
| Maryland | 415 | $466 million |
| Michigan | 364 | $460 million |
| Washington | 280 | $401 million |
| Georgia | 338 | $383 million |
| Tennessee | 281 | $379 million |
| Missouri | 292 | $365 million |
| Wisconsin | 251 | $335 million |
| Colorado | 320 | $334 million |
| Minnesota | 265 | $309 million |
| Florida | 241 | $293 million |
| Connecticut | 250 | $279 million |
| Virginia | 240 | $278 million |
| Alabama | 185 | $235 million |
| Indiana | 135 | $197 million |
| Arizona | 136 | $179 million |
| Utah | 141 | $140 million |
| Iowa | 112 | $137 million |
| Oregon | 116 | $129 million |
| New Jersey | 85 | $105 million |
| Louisiana | 85 | $93.7 million |
| Rhode Island | 114 | $93.3 million |
| Kentucky | 89 | $85.8 million |
| South Carolina | 95 | $81.4 million |
| District of Columbia | 57 | $66.4 million |
| Nebraska | 47 | $55.7 million |
| Oklahoma | 37 | $45.2 million |
| Vermont | 34 | $36.6 million |
| Kansas | 32 | $29.7 million |
| Delaware | 24 | $27.7 million |
| Mississippi | 36 | $26.8 million |
| New Hampshire | 19 | $19.6 million |
| Arkansas | 19 | $19.0 million |
| Maine | 12 | $15.3 million |
| New Mexico | 13 | $14.3 million |
| West Virginia | 15 | $11.7 million |
| Hawaii | 11 | $6.7 million |
| Nevada | 10 | $5.3 million |
| Montana | 4 | $4.8 million |
| North Dakota | 4 | $4.6 million |
| South Dakota | 4 | $4.0 million |
| Alaska | 2 | $2.9 million |
| Idaho | 3 | $1.1 million |
| Wyoming | 2 | $821,275 |